THCV Neutral Antagonism for CB1 Receptor Side Effect Reduction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for conditions like obesity, schizophrenia, epilepsy, and cognitive disorders using CB1 cannabinoid receptor agonists often result in adverse side effects due to their inverse agonist properties, which can exacerbate constitutive receptor activity, whereas neutral antagonists are less common and more effective with fewer side effects.
Innovation Solution
The use of tetrahydrocannabivarin (THCV) as a neutral antagonist of CB1 and CB2 cannabinoid receptors, which blocks receptor activation without affecting constitutive activity, thereby reducing side effects and providing therapeutic benefits for conditions such as obesity, schizophrenia, and epilepsy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If inverse agonist (SR141716A) is used to treat obesity and appetite disorders, then appetite suppression is achieved, but adverse side effects occur due to attenuation of constitutive CB1 receptor activity
Solution Approach 1:
The patent changes the pharmacological parameter of CB1 receptor interaction from inverse agonism to neutral antagonism. THCV binds to CB1 receptors with high affinity but does not alter constitutive activity, thereby blocking endogenous agonist effects without producing inverse agonist effects. This parameter change resolves the contradiction by maintaining appetite suppression efficacy while eliminating adverse side effects associated with constitutive activity attenuation.
2Productivity
If CB1 receptor antagonism is used to treat obesity, then appetite regulation is improved, but CB1-mediated functions such as mood, sleep and pain relief are adversely affected
Solution Approach 1:
The patent applies local quality by creating different pharmacological effects in different physiological contexts. THCV acts as a neutral antagonist in appetite regulation (blocking endogenous agonist effects) while leaving constitutive CB1 activity unchanged in other physiological systems. This allows selective modulation of CB1-mediated functions, improving appetite regulation without adversely affecting mood, sleep, and pain relief.
3Productivity
If inverse agonist activity is used to block CB1 receptors, then therapeutic effects are achieved, but complexity of pharmacological profile increases
Solution Approach 1:
The patent inverts the conventional approach by using a neutral antagonist instead of an inverse agonist. Rather than actively suppressing constitutive CB1 activity (inverse agonism), THCV simply blocks endogenous agonist binding without altering basal receptor tone. This inversion simplifies the pharmacological profile by eliminating inverse agonist effects while maintaining therapeutic benefits through selective antagonism of CB1-mediated appetite regulation.
Data Source
AI summary
The invention relates to the use of one or more cannabinoids in the manufacture of medicaments for use in the treatment of diseases and conditions benefiting from neutral antagonism of the CB, cannabinoid receptor. Preferably the cannabinoid is tetrahydrocannabivarin (THCV). Preferably the diseases and conditions to be treated are taken from the group: obesity, schizophrenia, epilepsy, cognitive disorders such as Alzheimer's, bone disorders, bulimia, obesity associated with type II diabetes (non-insulin dependant diabetes) and in the treatment of drug, alcohol and nicotine abuse or dependency.